NASDAQ:IMMU Immunomedics (IMMU) Stock Price, News & Analysis → Moonshot Coins for the Current Crypto Run (From Crypto 101 Media) (Ad) Free IMMU Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$87.86▼$87.8650-Day Range$85.08▼$87.8652-Week Range$8.80▼$87.93VolumeN/AAverage Volume4.01 million shsMarket Capitalization$20.31 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Immunomedics alerts: Email Address Ad Chaikin AnalyticsMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in seven months. So if you currently own NVIDIA (NVDA)... Or were thinking of buying it in the weeks ahead... I urge you to review my recent interview with 50-year Wall Street legend Marc Chaikin.You can watch it here. About Immunomedics Stock (NASDAQ:IMMU)Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.Read More Ad Chaikin AnalyticsMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in seven months. So if you currently own NVIDIA (NVDA)... Or were thinking of buying it in the weeks ahead... I urge you to review my recent interview with 50-year Wall Street legend Marc Chaikin.You can watch it here. IMMU Stock News HeadlinesMay 9, 2024 | finance.yahoo.comDecoding Gilead Sciences Inc (GILD): A Strategic SWOT InsightMay 6, 2024 | benzinga.comGilead Sciences Unusual Options Activity For May 06May 3, 2024 | bizjournals.comGilead cuts jobs, trims drugs amid deeper biopharma pullbackApril 25, 2024 | msn.comGilead Sciences (GILD) Q1 2024 Earnings Call TranscriptApril 25, 2024 | marketwatch.comGilead Sciences Posts Higher 1Q Sales, Swings to Loss on ChargesApril 25, 2024 | msn.comGilead posts quarterly loss on acquisition charge, revenue rises 5%April 19, 2024 | markets.businessinsider.comThe Analyst Verdict: Gilead Sciences In The Eyes Of 12 ExpertsApril 18, 2024 | benzinga.comWhat the Options Market Tells Us About Gilead SciencesApril 15, 2024 | finance.yahoo.comNorthStar Appoints Peter Pfreundschuh to Board of ManagersMarch 6, 2024 | finance.yahoo.comGilead bets on ‘trispecifics’ in latest cancer drug dealFebruary 29, 2024 | finance.yahoo.comAbingworth invests in Trodelvy development in deal with GileadFebruary 13, 2024 | msn.comGilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to PipelineFebruary 12, 2024 | finance.yahoo.comGilead Sciences, Inc.: Gilead: Maintaining Our $97 Fair Value Estimate as CymaBay Acquisition Looks Like a Good FitFebruary 12, 2024 | finance.yahoo.comGilead to buy CymaBay in $4.3B deal for liver disease drugFebruary 7, 2024 | finance.yahoo.comGilead Sciences, Inc.: Gilead Earnings: Maintaining $97 Fair Value Estimate as HIV and Oncology Catalysts ApproachJanuary 22, 2024 | finance.yahoo.comGilead Sciences, Inc.: Gilead: Trodelvy Lung Cancer Data Disappoints, but No Changes to Our Fair Value EstimateJanuary 16, 2024 | finance.yahoo.comArvinas Appoints Jared Freedberg as General CounselJanuary 9, 2024 | finance.yahoo.comNeuroTrauma Sciences Appoints William Fricker, CPA, MBA, as Chief Financial OfficerNovember 15, 2023 | benzinga.comGilead Sciences's Options: A Look at What the Big Money is ThinkingNovember 9, 2023 | benzinga.comA Closer Look at Gilead Sciences's Options Market DynamicsNovember 8, 2023 | finance.yahoo.comGilead Sciences, Inc.: Gilead Earnings: Maintaining Our $97 FVE Following In-Line HIV and Oncology PerformanceNovember 6, 2023 | bizjournals.comGilead sues former CFO of Immunomedics to claw back $4 millionNovember 6, 2023 | bizjournals.comDaily Digest: Slack CEO departs; Big East Bay battery factory opensOctober 29, 2023 | realmoney.thestreet.comSpate of Deal News Juices Start of This Week's TradingSeptember 14, 2023 | finance.yahoo.comUnraveling Gilead Sciences Inc's Dividend Performance and SustainabilitySee More Headlines Receive IMMU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunomedics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2020Today6/10/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic Substances Sub-IndustryBiotechnology Current SymbolNASDAQ:IMMU CUSIP45290710 CIK722830 Webwww.immunomedics.com Phone973-605-8200FaxN/AEmployees366Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-357,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-132.40% Return on Assets-51.32% Debt Debt-to-Equity RatioN/A Current Ratio12.84 Quick Ratio12.58 Sales & Book Value Annual Sales$290,000.00 Price / Sales70,028.66 Cash FlowN/A Price / Cash FlowN/A Book Value$1.38 per share Price / Book63.67Miscellaneous Outstanding Shares231,144,000Free FloatN/AMarket Cap$20.31 billion OptionableOptionable Beta2.90 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Behzad Aghazadeh Ph.D. (Age 49)Exec. Chairman Comp: $147.53kMr. Usama Malik (Age 45)CFO & Chief Bus. Officer Comp: $533.39kMr. Brendan P. Delaney (Age 45)Chief Commercial Officer Comp: $527.63kMr. Bryan Ball (Age 50)Chief Quality Officer Comp: $646.48kMr. William Fricker (Age 55)Principal Accounting Officer, Exec. Director & Corp. Controller Ms. Phyllis ParkerDirector of Admin.Dr. Chau ChengSr. Director of Investor RelationsMr. Jared Freedberg (Age 52)Gen. Counsel & Corp. Sec. Mr. Kurt J. W. Andrews (Age 51)Chief HR Officer Dr. Loretta M. Itri (Age 70)Chief Medical Officer More ExecutivesKey CompetitorsLantheusNASDAQ:LNTHNeogenNASDAQ:NEOGQuidelOrthoNASDAQ:QDELIntellia TherapeuticsNASDAQ:NTLAMeridian BioscienceNASDAQ:VIVOView All Competitors Should I Buy Immunomedics Stock? IMMU Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Immunomedics, Inc.: Immunomedics, Inc. recently announced a groundbreaking FDA approval for their latest cancer treatment, which is expected to significantly boost revenue and market share in the oncology sector. The company's stock price has shown a steady upward trend over the past few quarters, indicating positive investor sentiment and potential for capital gains. Immunomedics has a strong pipeline of innovative biopharmaceutical products in late-stage development, promising future growth and diversification. Recent collaborations with leading research institutions have enhanced Immunomedics' research capabilities and positioned the company as a key player in cutting-edge medical advancements. With a solid financial position and prudent management, Immunomedics is well-equipped to weather market fluctuations and capitalize on strategic opportunities for expansion. Cons Investors should be bearish about investing in Immunomedics, Inc. for these reasons: Despite recent successes, Immunomedics faces intense competition in the biopharmaceutical industry, which could impact market share and profitability in the long run. Regulatory uncertainties surrounding drug approvals and pricing policies may pose risks to Immunomedics' revenue streams and hinder investor confidence. The company's heavy reliance on a few key products for revenue generation exposes it to market volatility and potential disruptions in product supply chains. Fluctuations in research and development costs could impact Immunomedics' bottom line and strain financial resources, affecting shareholder returns. Investing in biopharmaceutical companies like Immunomedics carries inherent risks related to clinical trial outcomes, regulatory compliance, and market acceptance of new treatments. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, June 8, 2024. Please send any questions or comments about these Immunomedics pros and cons to contact@marketbeat.com. IMMU Stock Analysis - Frequently Asked Questions How were Immunomedics' earnings last quarter? Immunomedics, Inc. (NASDAQ:IMMU) released its earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.39. The biopharmaceutical company earned $20.07 million during the quarter, compared to the consensus estimate of $24.81 million. What other stocks do shareholders of Immunomedics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include Micron Technology (MU), NVIDIA (NVDA), Seagen (SGEN), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Intel (INTC). This page (NASDAQ:IMMU) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunomedics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunomedics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
